# Floatz vs Unlearn.AI

Floatz records 253 monthly visits with -36.8% month-over-month growth and Contact for Pricing pricing. Unlearn.AI records 17,107 monthly visits with -32.5% growth and Contact for Pricing pricing.

| Metric | [Floatz](https://openaitools.app/tool/floatz-ai) | [Unlearn.AI](https://openaitools.app/tool/unlearn-ai) |
| :--- | :--- | :--- |
| Website URL | https://floatz.ai | https://unlearn.ai |
| Categories | AI Healthcare, AI Research Tool, AI For Data Analytics, AI Report Generator | AI Healthcare, AI Research Tool, AI Predictions, AI Models |
| Pricing Model | Contact for Pricing | Contact for Pricing |
| Monthly Visits | 253 | 17,107 |
| MoM Growth Rate | -36.8% | -32.5% |
| Primary Market | Switzerland | United States |
| Direct Visits | 94 | 7,493 |
| Review Score | 3.8 | 4.4 |
| Saved Count | 17 | 1 |
| Supported Platforms | Website | Website |

## Floatz

Floatz positions itself as an AI research engine for life-science questions. Rather than relying on manual literature reviews, it indexes and summarises scientific publications so users can interrogate a therapeutic area, a target or a company's science and get a consolidated view in minutes rather than weeks.

The platform is aimed at two overlapping audiences: investors doing scientific due diligence on biotech and life-science assets, and research teams who need fast, cited groundwork on drug targets, pathways and emerging evidence. Results are presented as structured summaries with the underlying papers kept as traceable references.

Floatz does not publish self-serve pricing; the site directs buyers to request access, which is typical of enterprise/investor-grade research tools where seats and data volumes are negotiated. Because capabilities and data coverage evolve quickly, it is worth confirming the current scope of literature coverage directly with the vendor.

**Pricing & Plans:** Contact for pricing — Floatz does not list public plans on its website and directs interested users to get in touch.

- **Scientific literature search and analysis:** Search and analyse large bodies of scientific papers to answer specific research or therapeutic-area questions.
- **Structured summaries with sources:** Distils dense literature into readable, source-linked summaries so findings can be traced back to the original publications.
- **Target and pathway discovery support:** Helps surface high-potential drug targets and relevant biological pathways across large document sets.
- **Due-diligence workflows for investors:** Frames evidence around scientific risk so life-science investors can review a thesis before capital is committed.
- **Built for non-programmers:** A web interface aimed at analysts and researchers rather than bioinformaticians, so no coding or command-line work is required.

**Strengths:** Focuses on life-science evidence rather than generic text, so outputs are framed around targets, pathways and scientific risk; Saves the weeks normally spent on manual literature triage; Aims to keep summaries traceable to source publications, which matters for audit and investment memos; Browser-based, so analysts and investors can use it without a bioinformatics stack

**Limitations:** No public pricing or self-serve trial published on the site, so onboarding likely requires a sales conversation; Coverage and accuracy depend on the literature and data sources it indexes, which are not fully documented publicly; Best suited to life-science questions — it is not a general-purpose research assistant

[Profile (Markdown)](https://openaitools.app/tool/floatz-ai.md)

## Unlearn.AI

Unlearn.AI works with biopharma sponsors and clinical research teams at three points in a trial's lifecycle: before the protocol is finalized, while the study is running, and after readout. In design, teams model the patients they expect to enroll and pressure-test sample size, eligibility criteria, endpoints, and comparators before locking the protocol. The company's PROCOVA method — described as EMA-qualified and FDA-supported — applies twin-based covariate adjustment to reduce sample size in randomized controlled trials while holding statistical power, or to increase power without adding patients.

Mid-study, Unlearn supports pre-specified twin-based analyses that tighten interim estimates without enrolling anyone new, and lets teams re-run design scenarios when new evidence — a competitor readout, a fresh publication, or blinded data drifting from assumptions — changes the picture. After a study reads out, digital twins are used to contextualize population, endpoints, and variability, improving sensitivity across endpoints and helping teams re-evaluate historical trial data with regulatory-aligned methods.

Unlearn publishes concrete case outcomes: a 20% sample-size reduction built into a Phase 1/2 design with roughly $2M in savings, a 33% smaller control arm and four-plus months of enrollment time saved in a re-analysis of completed Phase 3 trials from a top-5 global sponsor, and a completed Phase 3 ALS trial re-analyzed to keep full power with 92 fewer participants. The company partners with sponsors including Trace Neuroscience, QurAlis, Acumen Pharmaceuticals, SOLA Biosciences, VectorY Therapeutics, and CHDI Foundation, and states it works with top global pharma companies. Unlearn does not publish list pricing; engagements are scoped through direct contact.

**Pricing & Plans:** Enterprise, contact-for-pricing model. Unlearn does not publish standard subscription tiers; engagements are scoped per study or program after a conversation with the team.

- **AI-generated patient digital twins:** Model-based forecasts of each participant's clinical outcomes, generated from baseline data already collected, that act as a virtual comparator or as additional information per enrolled patient.
- **PROCOVA design and analysis method:** A twin-based covariate adjustment approach that Unlearn describes as EMA-qualified and FDA-supported, used to reduce sample size in randomized controlled trials while maintaining power.
- **Trial design scenario modeling:** Build and compare design scenarios — endpoints, eligibility criteria, sample size, assumptions — so governance decisions are made with quantified tradeoffs instead of positions.
- **Interim and readout analysis support:** Pre-specified twin-based analyses added to the statistical analysis plan before unblinding, plus twin-adjusted analysis delivered at interim and at readout.
- **Externally controlled study design:** Design single-arm and externally controlled studies where randomization is not an option, selecting eligibility criteria that give open-label studies the best chance of a clear readout.

**Strengths:** Digital twins are generated from data already collected, so no extra patients are required to gain information; Publicly reported, quantified outcomes — sample-size reductions, cost savings, and enrollment time saved — rather than only qualitative claims; Covers the whole trial lifecycle: design, interim, and readout, not just one decision point; Named collaborations with biotech and pharma sponsors, plus regulatory-aligned methodology

**Limitations:** Pricing is not published, so budgeting requires a direct sales conversation; The value proposition depends on regulatory acceptance of twin-based methods, which varies by agency and indication; Best suited to sponsors with existing clinical data and statistical teams; not a self-serve tool; Public metrics come from specific studies and may not transfer directly to other indications

[Profile (Markdown)](https://openaitools.app/tool/unlearn-ai.md)

## Frequently Asked Questions

### How do Floatz and Unlearn.AI compare in monthly traffic?

Floatz has 253 monthly visits, while Unlearn.AI has 17,107. Traffic estimates describe audience size, not product quality.

### How do their growth rates compare?

Floatz has a month-over-month growth rate of -36.8%; Unlearn.AI has -32.5%.

### How does pricing compare?

Floatz: Contact for Pricing. Contact for pricing — Floatz does not list public plans on its website and directs interested users to get in touch. Unlearn.AI: Contact for Pricing. Enterprise, contact-for-pricing model. Unlearn does not publish standard subscription tiers; engagements are scoped per study or program after a conversation with the team.

## Alternatives

| # | Tool Name | Monthly Visits | MoM Growth Rate | Pricing Model | Summary | Profile (Markdown) |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 1 | [Semantic Scholar](https://openaitools.app/tool/semantic-scholar) | 8,198,672 | +5.8% | Free | A free, AI-powered academic search engine for 240M+ papers across every scientific field | [.md](https://openaitools.app/tool/semantic-scholar.md) |
| 2 | [Consensus](https://openaitools.app/tool/consensus) | 6,014,388 | -1.2% | Freemium | AI academic search engine for peer-reviewed science | [.md](https://openaitools.app/tool/consensus.md) |
| 3 | [SciSpace](https://openaitools.app/tool/scispace) | 4,464,111 | +8.6% | Freemium | AI research platform for reading, understanding and writing scientific papers | [.md](https://openaitools.app/tool/scispace.md) |
| 4 | [Elicit](https://openaitools.app/tool/elicit) | 1,751,507 | +3.1% | Freemium | AI research assistant for evidence-based literature review and synthesis | [.md](https://openaitools.app/tool/elicit.md) |
| 5 | [Scite](https://openaitools.app/tool/scite) | 841,974 | +1.1% | Free Trial, Contact for Pricing | AI answers grounded in 300M+ scholarly full texts | [.md](https://openaitools.app/tool/scite.md) |
| 6 | [Dr.Oracle](https://openaitools.app/tool/dr-oracle) | 723,847 | -1.2% | Free Trial | Guideline-directed medical answers with citations, built for clinicians | [.md](https://openaitools.app/tool/dr-oracle.md) |
| 7 | [Upheal](https://openaitools.app/tool/upheal-io) | 347,782 | -2.1% | Freemium, Free Trial, Contact for Pricing | AI therapy notes and an AI-native EHR built for mental health professionals. | [.md](https://openaitools.app/tool/upheal-io.md) |
| 8 | [Delve AI](https://openaitools.app/tool/delve) | 49,025 | -4.6% | Freemium | Generate data-backed personas, digital twins and synthetic research on demand | [.md](https://openaitools.app/tool/delve.md) |
| 9 | [Oatmeal Health](https://openaitools.app/tool/oatmeal-health) | 40,264 | -44.9% | Contact for Pricing | AI lung cancer screening that finds eligible patients and scores every nodule | [.md](https://openaitools.app/tool/oatmeal-health.md) |
| 10 | [Amsflow](https://openaitools.app/tool/amsflow) | 37,303 | +72.2% | Free Trial, Paid | Institutional-depth market research with an AI copilot that builds, backtests, and screens for you | [.md](https://openaitools.app/tool/amsflow.md) |

---
Source: https://openaitools.app/compare/floatz-ai-vs-unlearn-ai

More Markdown: [Categories](https://openaitools.app/categories.md) · [Traffic rankings](https://openaitools.app/rankings.md) · [llms.txt](https://openaitools.app/llms.txt)
